Results: Medexus Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Medexus Pharmaceuticals Inc. (TSE:MDP) investors will be delighted, with the company turning in some strong numbers with its latest results. It was a solid earnings report, with revenues and statutory earnings per share (EPS) both coming in strong. Revenues were 11% higher than the analysts had forecast, at US$29m, while EPS were US$0.03 beating analyst models by 83%. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
Taking into account the latest results, the current consensus from Medexus Pharmaceuticals' six analysts is for revenues of US$118.9m in 2027. This would reflect a solid 10% increase on its revenue over the past 12 months. Earnings are expected to improve, with Medexus Pharmaceuticals forecast to report a statutory profit of US$0.15 per share. Before this earnings report, the analysts had been forecasting revenues of US$114.4m and earnings per share (EPS) of US$0.16 in 2027. So it's pretty clear consensus is mixed on Medexus Pharmaceuticals after the latest results; whilethe analysts lifted revenue numbers, they also administered a minor downgrade to per-share earnings expectations.
View our latest analysis for Medexus Pharmaceuticals
The analysts also upgraded Medexus Pharmaceuticals' price target 5.4% to CA$7.64, implying that the higher revenue expected to generate enough value to offset the forecast decline in earnings. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic Medexus Pharmaceuticals analyst has a price target of CA$9.00 per share, while the most pessimistic values it at CA$6.50. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.
Of course, another way to look at these forecasts is to place them into context against the industry itself. The analysts are definitely expecting Medexus Pharmaceuticals' growth to accelerate, with the forecast 22% annualised growth to the end of 2027 ranking favourably alongside historical growth of 4.7% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 9.5% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Medexus Pharmaceuticals to grow faster than the wider industry.
The Bottom Line
The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for Medexus Pharmaceuticals going out to 2029, and you can see them free on our platform here.
You can also view our analysis of Medexus Pharmaceuticals' balance sheet, and whether we think Medexus Pharmaceuticals is carrying too much debt, for free on our platform here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.